ELF participated in the annual general meeting of the AirPROM project (Airway Disease Predicting Outcomes through Patient Specific Computational Modelling) on 20-21 April, 2016 in Leicester, UK.
During the meeting, consortium members discussed AirPROM achievements and how results, services and products will be delivered after the project ends.
AirPROM is a European Union (EU) project which aimed to develop computer models to improve the treatment of airway conditions like asthma and chronic obstructive pulmonary disease (COPD).
These models will help scientists to look at how air flows through the airways in people with asthma and COPD. They will be able to use these models to test new treatments to see how the airways of different people respond to each treatment.
The overall aim of the project is to develop more personalised treatments to help improve the lives of people with asthma and COPD.
In the AGM, project leaders reported that the design and validation of computer and physical models of the lungs are in their final stages. Project leaders agreed on a plan to complete data analysis, identify potential for commercialisation, complete all publications and communicate AirPROM findings to different targets.
AirPROM consortium members are committed to continuing their work, which will see results of the project delivered in autumn 2016 and early 2017.
On 31 May, the project’s major achievements and potential future developments in the field will be presented to Members of the European Parliament (MEPs) and policy-makers at the AirPROM Final Conference at the European Parliament in Brussels.
The event will be hosted by co-Chair of Europe of Freedom and Direct Democracy Group, MEP David Borrelli and MEP Sirpa Pietikainen, who are both members of the European Parliament Interest Group on Allergy and Asthma.
Find out more about AirPROM, by signing up for the newsletter or following AirPROM on Twitter, Linkedin and Youtube.
Learn about the factors that can cause lung disease and the ways to reduce your contact with them.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.